RxDoctor Payments Data

Amanda Lucas, NP

Family · Houma, LANPI 1871079822

Payments from drug & device makers

$1,705in general payments, 2019–2025

Across 54 payments — averaging $31.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$340
  • Lilly USA, LLC$287
  • Novo Nordisk$263
  • AbbVie$209
  • Mayne Pharma Commercial LLC$157
  • Gilead$123
  • plus $326 from 10 others

What the payments were for

  • Food & beverage$1,705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,705 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$7,678
Medicare patients
31
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$74,554
MounjaroTirzepatide44$67,558
JardianceEmpagliflozin61$64,094
TrulicityDulaglutide29$39,910
Tresiba Flextouch U-100Insulin Degludec22$18,558
TradjentaLinagliptin13$9,202
Fiasp FlextouchInsulin Aspart (Niacinamide)11$6,688
Novolog FlexpenInsulin Aspart32$5,852
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,642
Insulin Lispro Kwikpen U-100Insulin Lispro23$3,188
Nano 2nd Gen Pen NeedlePen Needle, Diabetic23$2,996
Metformin Hcl67$838
Atorvastatin Calcium71$655
Albuterol Sulfate HfaAlbuterol Sulfate21$598
Omeprazole30$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$287$107,46773 claims
Novo NordiskOzempic$263$74,55439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.

Other family in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →